Investigating the Immunogenic Cell Death-Dependent Subtypes and Prognostic Signature of Triple-Negative Breast Cancer-Reference-Cited by-同舟云学术

Investigating the Immunogenic Cell Death-Dependent Subtypes and Prognostic Signature of Triple-Negative Breast Cancer

Published:2024-02 Issue:1 Volume:4 Page:34-45
ISSN:2730-583X
Container-title:Phenomics
language:en
Short-container-title:Phenomics

Author:

Shi Youyang^ORCID,Wu Yuanyuan^ORCID,Li Feifei^ORCID,Jiang Kexin^ORCID,Fang Xiaofang^ORCID,Wang Yu^ORCID,Song Xiaoyun^ORCID,Wang Rui^ORCID,Chen Lixin^ORCID,Zheng Jinzhou^ORCID,Wu Chunyu^ORCID,Qin Yuenong^ORCID,Liu Xiaofei^ORCID,Liu Sheng^ORCID

Funder

National Natural Science Foundation of China

Natural Science Foundation of Shandong Province

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s43657-023-00133-x.pdf

Reference26 articles.

1. Abouelnazar FA, Zhang X, Wang M, Zhang J, Yu D, Zang X et al (2023) The new advance of SALL4 in cancer: function, regulation, and implication. J Clin Lab Anal. https://doi.org/10.1002/jcla.24927

2. Adams S, Gray RJ, Demaria S, Goldstein L, Perez EA, Shulman LN et al (2014) Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol 32(27):2959–2966. https://doi.org/10.1200/JCO.2013.55.0491

3. Asleh K, Brauer HA, Sullivan A, Lauttia S, Lindman H, Nielsen TO et al (2020) Predictive biomarkers for adjuvant capecitabine benefit in early-stage triple-negative breast cancer in the FinXX Clinical Trial. Clin Cancer Res 26(11):2603–2614. https://doi.org/10.1158/1078-0432.CCR-19-1945

4. Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK et al (2008) Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 14(5):1368–1376. https://doi.org/10.1158/1078-0432.CCR-07-1658

5. Diana A, Carlino F, Franzese E, Oikonomidou O, Criscitiello C, De Vita F et al (2020) Early triple negative breast cancer: conventional treatment and emerging therapeutic landscapes. Cancers (basel). https://doi.org/10.3390/cancers12040819